Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bone Biologics, a company developing a proprietary protein for use in bone regenerative medicine using the patented recombinant human protein known as UCB-1 (or Nell-1) for use with patients undergoing spinal fusion, has announced today the completion of a reverse merger of privately held Bone Biologics, Inc. and AFH Acquisition X, Inc, a fully-reporting company with the Securities and Exchange Commission.
Subscribe to our email newsletter
Upon completion of the merger, the combined company changed its name to Bone Biologics, Corp and anticipates that trading in the Company’s common stock will commence on the OTC Bulletin Board following regulatory approvals.
Following the completion of the merger, the Musculoskeletal Transplant Foundation (MTF), the nation’s leading tissue bank and majority shareholder, remains as the largest shareholder.
For the last eight years MTF has been an investor in Bone Biologics and will continue its support for the Company’s development of Bone Biologics revolutionary bone growth factor. In connection with the merger, Bruce Stroever, the president and CEO of MTF, will serve as Chairman of the Bone Biologics Board and Michael Schuler, MTF’s Vice President of New Business Development, will serve as Chief Executive Officer. William Jay Treat, PhD. was appointed the Company’s President and Chief Technology Officer.
Nell-1, a bone growth factor has been developed by Bone Biologics, Inc. in partnership with University of California, Los Angeles (UCLA) as a more specific alternative to other bone growth factors used in health care today.
In large animal studies, Nell-1 exhibited none of the side effects currently associated with other bone growth factors including ectopic bone growth, extraneous bone growth or cyst formation. The next phase will be completing the development and testing work needed to seek regulatory approval for the initial pilot study in human clinical trials.
William Jay Treat said, "We are pleased with the completion of this merger which will now allow the company to move from basic research to preparation for clinical trials. With our aging population and the growing need for regenerative bone solutions, we are optimistic that Bone Biologics will be an attractive and preferred solution in this dynamic and growing marketplace."